Meet the PH Therapeutics Team

Allan Lawrie, PhD

Allan Lawrie is a MRC Career Development Award Fellow, and University Senior Fellow. Allan leads the Pulmonary Vascular Research Group in the Department of Cardiovascular Sciences at the University of Sheffield, UK. After completion of his PhD at the University of Sheffield he undertook a Post-doctoral Fellowship under the mentorship of Professor Marlene Rabinovitch at Stanford University, California. During this time Allan developed his interest in understanding the molecular mechanisms involved in the pathogenesis of pulmonary hypertension Allan returned to the University of Sheffield at the end of 2004 to establish his own laboratory and continue his studies into the pathogenesis of pulmonary hypertension. Working closely with clinical colleagues in the Sheffield Pulmonary Vascular Disease Unit, his current interests include investigating the pathogenic role of TNF superfamily members OPG and TRAIL in pulmonary arterial hypertension. Recent research published in the Journal of Experimental Medicine has demonstrated that antibody blockade of TRAIL reverses experimental pulmonary arterial hypertension.

Martin Whitaker, PhD

Martin Whitaker is a non-executive director at PH Therapeutics a spin-out company from the University of Sheffield where he is a Business Manager for Fusion IP PLC. Martin is currently Chief Executive Officer of the Fusion IP company, Diurnal, with overall responsibility for delivering the company’s commercial objectives and has over 10 years’ experience in the pharmaceutical industry. Martin is also Director of Faveo Limited commercialising intellectual property in the apparel field. Prior to this Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital backed drug delivery company spun out of the University of Nottingham. Martin had overall responsibility for product development, building and developing the scientific team as well being part of the fund raising team that secured £3M in funding over a four year period. Martin is a biochemist by background and has a PhD in Pharmaceutical Science from the University of Nottingham. Martin also spent a year working for Pfizer in the Pharmaceutical R&D Department at Pfizer Global R&D (UK).

Peter Grant, PhD

Peter Grant is a founder director of Fusion IP PLC, an AIM listed company involved in commercialising university-based research. Peter is also a non-executive director of Adjuvantix Limited and Asterion Limited, all companies acting in the field of human healthcare. Following his PhD, Peter joined Genzyme UK as a Senior Research Scientist working within the clinical diagnostics division. He moved to Celltech from Genzyme, and was then recruited by Sir Christopher Evans to join the start-up team at Enzymatix Limited where he became the Head of R&D, spanning five business areas. Two of these were later spun out to form Chiros (later Chiroscience) and Celsis with Peter as a co-founder and R&D Director. Following venture capital funding rounds Celsis was successfully floated on the London Stock Exchange in June 1993. Peter completed his tenure at Celsis as Director of Business Development and Technology leaving in 2002 to set up Fusion IP PLC.

Craig Richardson

Prior to joining Fusion IP Craig was an Investment Manager at Inventages, one of the world’s largest healthcare focused venture capital funds. He has also worked in business development for a number of early-stage life science companies and in new product development for Glaxo Wellcome. Craig has a first class honours degree in Pharmacy from Cardiff University and a PhD from the School of Pharmacy, University of Nottingham. He also holds an MBA with distinction from the University of Warwick where he was awarded a Sainsbury Management Fellowship from the Royal Academy of Engineering.